Evaluation of the impact of gamma-aminobutyric acid on diabetic retinopathy in a large US population-based cohort.

After successful propensity-score matched, there were 110,495 (6-months), 99,187 (1-year), 63,194 (3-years), and 40,810 (5-years) diabetic retinopathy-naive study patients with the respective GABAergic prescription durations of interest.

Study patients (n=14,644) with baseline mild/moderate nonproliferative diabetic retinopathy had a significantly reduced hazard of progressing to severe nonproliferative diabetic retinopathy, proliferative diabetic retinopathy, or diabetic retinopathy interventions with 6-months (HR 0.75, 95% CI 0.68-0.82) and 1-year (HR 0.69, 95% CI 0.73, 0.86) GABAergic exposure.